DDInter1833 DDInter122
Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Tolvaptan {u} (Compound) resembles {v} (Compound) Conivaptan
Tolvaptan {u} (Compound) binds {v} (Gene) AVPR1A
Tolvaptan {u} (Compound) causes {v} (Side Effect) Renal impairment
Tolvaptan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Tolvaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Tolvaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Tolvaptan {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Tolvaptan {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Tolvaptan (Compound) resembles Conivaptan (Compound)
Tolvaptan (Compound) binds AVPR1A (Gene)
Tolvaptan (Compound) causes Renal impairment (Side Effect)
Tolvaptan may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Tolvaptan may lead to a major life threatening interaction when taken with Leflunomide
Tolvaptan may lead to a major life threatening interaction when taken with Lumacaftor